Cargando…

Second primary malignancy among malignant solid tumor survivors aged 85 years and older

The cancer burden in the oldest old has increased rapidly. This study aimed to investigate the epidemiology of second primary malignancy (SPM) in malignant solid tumor survivors aged 85 years and older utilizing the Surveillance, Epidemiology, and End Results (SEER) database. A total of 128,466 mali...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhijia, Liu, Fei, Qu, Yanlin, Qiu, Liqian, Zhang, Liqun, Yang, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492691/
https://www.ncbi.nlm.nih.gov/pubmed/34611235
http://dx.doi.org/10.1038/s41598-021-99260-6
_version_ 1784578971804893184
author Zhang, Zhijia
Liu, Fei
Qu, Yanlin
Qiu, Liqian
Zhang, Liqun
Yang, Qiao
author_facet Zhang, Zhijia
Liu, Fei
Qu, Yanlin
Qiu, Liqian
Zhang, Liqun
Yang, Qiao
author_sort Zhang, Zhijia
collection PubMed
description The cancer burden in the oldest old has increased rapidly. This study aimed to investigate the epidemiology of second primary malignancy (SPM) in malignant solid tumor survivors aged 85 years and older utilizing the Surveillance, Epidemiology, and End Results (SEER) database. A total of 128,466 malignant solid tumor patients had been identified between 2000 and 2011, including 6774 patients who developed a SPM. The overall crude incidence of developing a SPM was 5.3%. Considering death as a competing event, the 3, 5, and 10-year cumulative incidence was 1.9%, 3.2%, and 5.4%, respectively. Relative younger age, male gender, surgery history, local stage and first primary malignancy (FPM) site located in the urinary system were related to higher cumulative incidence. A median time interval of 24.0 months was found between diagnosis of FPM and SPM. The most common SPM site was digestive system, whereas the least common was oral cavity and pharynx. The median overall survival (OS) was 49.0 months, and the median survival after SPM was 13.0 months. Relative older age, male gender and black race were associated with worse OS and survival after SPM, as well as higher hazard ratios of death. In conclusions, this study performed a comprehensive analysis of SPM among malignant solid tumor survivors aged 85 years and older. Additional studies are needed to characterize the specific cancer type of interest.
format Online
Article
Text
id pubmed-8492691
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84926912021-10-07 Second primary malignancy among malignant solid tumor survivors aged 85 years and older Zhang, Zhijia Liu, Fei Qu, Yanlin Qiu, Liqian Zhang, Liqun Yang, Qiao Sci Rep Article The cancer burden in the oldest old has increased rapidly. This study aimed to investigate the epidemiology of second primary malignancy (SPM) in malignant solid tumor survivors aged 85 years and older utilizing the Surveillance, Epidemiology, and End Results (SEER) database. A total of 128,466 malignant solid tumor patients had been identified between 2000 and 2011, including 6774 patients who developed a SPM. The overall crude incidence of developing a SPM was 5.3%. Considering death as a competing event, the 3, 5, and 10-year cumulative incidence was 1.9%, 3.2%, and 5.4%, respectively. Relative younger age, male gender, surgery history, local stage and first primary malignancy (FPM) site located in the urinary system were related to higher cumulative incidence. A median time interval of 24.0 months was found between diagnosis of FPM and SPM. The most common SPM site was digestive system, whereas the least common was oral cavity and pharynx. The median overall survival (OS) was 49.0 months, and the median survival after SPM was 13.0 months. Relative older age, male gender and black race were associated with worse OS and survival after SPM, as well as higher hazard ratios of death. In conclusions, this study performed a comprehensive analysis of SPM among malignant solid tumor survivors aged 85 years and older. Additional studies are needed to characterize the specific cancer type of interest. Nature Publishing Group UK 2021-10-05 /pmc/articles/PMC8492691/ /pubmed/34611235 http://dx.doi.org/10.1038/s41598-021-99260-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhang, Zhijia
Liu, Fei
Qu, Yanlin
Qiu, Liqian
Zhang, Liqun
Yang, Qiao
Second primary malignancy among malignant solid tumor survivors aged 85 years and older
title Second primary malignancy among malignant solid tumor survivors aged 85 years and older
title_full Second primary malignancy among malignant solid tumor survivors aged 85 years and older
title_fullStr Second primary malignancy among malignant solid tumor survivors aged 85 years and older
title_full_unstemmed Second primary malignancy among malignant solid tumor survivors aged 85 years and older
title_short Second primary malignancy among malignant solid tumor survivors aged 85 years and older
title_sort second primary malignancy among malignant solid tumor survivors aged 85 years and older
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492691/
https://www.ncbi.nlm.nih.gov/pubmed/34611235
http://dx.doi.org/10.1038/s41598-021-99260-6
work_keys_str_mv AT zhangzhijia secondprimarymalignancyamongmalignantsolidtumorsurvivorsaged85yearsandolder
AT liufei secondprimarymalignancyamongmalignantsolidtumorsurvivorsaged85yearsandolder
AT quyanlin secondprimarymalignancyamongmalignantsolidtumorsurvivorsaged85yearsandolder
AT qiuliqian secondprimarymalignancyamongmalignantsolidtumorsurvivorsaged85yearsandolder
AT zhangliqun secondprimarymalignancyamongmalignantsolidtumorsurvivorsaged85yearsandolder
AT yangqiao secondprimarymalignancyamongmalignantsolidtumorsurvivorsaged85yearsandolder